Stock ZTS ZOETIS INC.
Add to a list

Zoetis Inc. Share Price

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 02:30:03 24/01/2026 am IST 		5-day change 1st Jan Change
124.05 USD -0.28% Intraday chart for Zoetis Inc. -0.48% -1.41%
22/01 Escalate, De-Escalate, Repeat Zonebourse
22/01 Piper Sandler Downgrades Zoetis to Neutral From Overweight, Adjusts Price Target to $135 From $190 MT

Valuation: Zoetis Inc.

Capitalization 5.47TCr 4.65TCr 4.31TCr 4.03TCr 7.51TCr 5,02300Cr 7.96TCr 49TCr 20TCr 2,37100Cr 20TCr 20TCr 8,62600Cr P/E ratio 2025 *
20.7x
P/E ratio 2026 * 19.3x
Enterprise value 5.94TCr 5.05TCr 4.68TCr 4.37TCr 8.15TCr 5,45400Cr 8.64TCr 53TCr 21TCr 2,57500Cr 22TCr 22TCr 9,36700Cr EV / Sales 2025 *
6.29x
EV / Sales 2026 * 5.93x
Free-Float
88.45%
Yield 2025 *
1.6%
Yield 2026 * 1.8%
More valuation ratios * Estimated data

Chart: Zoetis Inc.

Dynamic Chart

Latest news: Zoetis Inc.

22/01 Escalate, De-Escalate, Repeat Zonebourse
22/01 Piper Sandler Downgrades Zoetis to Neutral From Overweight, Adjusts Price Target to $135 From $190 MT
22/01 Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix… Zonebourse
13/01 Zoetis CEO on Animal Health, Vaccines and Beef Prices MT
13/01 Zoetis Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM
17/12 Morgan Stanley Adjusts Zoetis Price Target to $160 From $175, Maintains Overweight Rating MT
16/12 Sector Update: Health Care Stocks Edge Higher Premarket Tuesday MT
16/12 The Fed's Favorite Numbers? Zonebourse
16/12 Zoetis Prices $1.75 Billion Convertible Notes Offering MT
16/12 Zoetis says co priced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 RE
15/12 Zoetis to Offer $1.75 Billion Convertible Notes Offering MT
15/12 Zoetis announces proposed $1.75 billion convertible senior notes offering RE
15/12 BofA Securities Downgrades Zoetis to Neutral From Buy MT
More news

Last Transcript: Zoetis Inc.

Logo Zoetis Inc.
Zoetis Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM
13/01
More transcripts

Analysts' recommendations: Zoetis Inc.

22/01 Piper Sandler Downgrades Zoetis to Neutral From Overweight, Adjusts Price Target to $135 From $190 MT
22/01 Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix… Zonebourse
17/12 Morgan Stanley Adjusts Zoetis Price Target to $160 From $175, Maintains Overweight Rating MT
15/12 BofA Securities Downgrades Zoetis to Neutral From Buy MT
10/12 HSBC Adjusts Zoetis Price Target to $140 From $180, Maintains Buy Rating MT
More recommendations

Press Releases: Zoetis Inc.

30/12 Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results BU
18/12 Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference BU
16/12 Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering BU
15/12 Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering BU
12/12 Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase BU
More press releases

News in other languages: Zoetis Inc.

27/12 3 géants français…et leur comparable américain méconnu
18/11 Wall Street : Traders, accrochez-vous
04/11 Wall Street : Le marché haussier prêt pour une correction ?
04/11 Bourse : Palantir déçoit, bioMérieux avertit, Edenred dévoile ses ambitions et Nintendo voit plus haut
04/11 IA un truc qui cloche ?
More news

Quotes and Performance

1 day-0.28%
1 week-0.48%
Current month-1.41%
1 month+0.41%
3 months-15.26%
6 months-19.16%
Current year-1.41%
More quotes

Course Extremes

1 week 121.65
Extreme 121.65
 127.12
1 month 121.65
Extreme 121.65
 131.13
Current year 121.65
Extreme 121.65
 131.13
1 year 115.25
Extreme 115.25
 177.4
3 years 115.25
Extreme 115.25
 201.92
5 years 115.25
Extreme 115.25
 249.27
10 years 38.26
Extreme 38.26
 249.27
More quotes

Managers and Directors: Zoetis Inc.

Manager TitleAgeSince
Kristin Peck CEO
 Chief Executive Officer 54 01/01/2020
Wetteny Joseph DFI
 Director of Finance/CFO 54 01/06/2021
Kevin Esch CTO
 Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Frank D'Amelio CHM
 Chairman 68 01/07/2012
Gregory Norden BRD
 Director/Board Member 68 01/01/2013
Michael McCallister CHM
 Chairman 73 26/06/2013
More insiders

ETFs: Zoetis Inc.

Name Varia. Jan 1. Weight AuM
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
+0.75%3.35% 26 M€
More ETFs: Zoetis Inc.

Veterinary Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
ZOETIS INC. Stock Zoetis Inc.
-0.28%-0.48%-25.70%-25.61% 5.48TCr
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-2.05%-0.53%+102.32%+84.43% 1.24TCr
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+1.05%+6.68%-17.84%+9.11% 418.73Cr
VIRBAC Stock Virbac
-0.82%+1.82%+20.17%+32.66% 360.77Cr
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-1.42%-1.48%+171.94%+66.03% 275.82Cr
VIMIAN GROUP AB Stock Vimian Group AB
-1.81%-8.07%-27.03%-7.89% 168.67Cr
PHIBRO ANIMAL HEALTH CORPORATION Stock Phibro Animal Health Corporation
-6.25%-5.02%+78.37%+152.66% 168.66Cr
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-0.39%+1.14%+17.06%+1.65% 133.24Cr
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-0.59%+7.88%+34.12%-34.13% 125.07Cr
VETOQUINOL SA Stock Vetoquinol SA
0.00%-0.82%+32.29%-2.43% 116.97Cr
Average -1.26%-1.28%+38.57%+27.65% 848.78Cr
Weighted average by Cap. -0.68%-0.51%+6.12%+2.12%
See all sector performances

Financials

2025 *2026 *
Net sales 944.08Cr 802.94Cr 744.25Cr 695.48Cr 1.3TCr 87TCr 1.37TCr 8.51TCr 3.38TCr 41TCr 3.54TCr 3.47TCr 1,49000Cr 991.47Cr 843.24Cr 781.6Cr 730.39Cr 1.36TCr 91TCr 1.44TCr 8.93TCr 3.55TCr 43TCr 3.72TCr 3.64TCr 1,56400Cr
Net income 267.74Cr 227.71Cr 211.07Cr 197.24Cr 367.69Cr 25TCr 389.72Cr 2.41TCr 957.64Cr 12TCr 1TCr 983.4Cr 42TCr 279.97Cr 238.11Cr 220.71Cr 206.24Cr 384.48Cr 26TCr 407.52Cr 2.52TCr 1TCr 12TCr 1.05TCr 1.03TCr 44TCr
Net Debt 469.23Cr 399.08Cr 369.91Cr 345.67Cr 644.4Cr 43TCr 683.01Cr 4.23TCr 1.68TCr 20TCr 1.76TCr 1.72TCr 74TCr 408.79Cr 347.68Cr 322.26Cr 301.15Cr 561.39Cr 38TCr 595.03Cr 3.68TCr 1.46TCr 18TCr 1.53TCr 1.5TCr 65TCr
More financial data * Estimated data

Company Profile

Logo Zoetis Inc.
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - companion animal (67.8%): cats and dogs (95.5% of net sales) and horses (4.5%); - livestock (31.3%): cattle (52.8% of sales), poultry (18.2%), swine (17.8%), fish (8.4%) and other (2.8%); - other (0.9%). Net sales break down by family of products into parasiticides (23.3%), vaccines (19.7%), dermatological products (17.9%), anti-infectives (11.9%), pain relievers (9.2%), diagnostic products (4.2%), medicated feed additives (3.2%) and other (10.6%). At the end of 2024, the group has 22 production sites worldwide. The United States accounts for 54.8% of net sales.
Employees
13,800
Sector
Pharmaceuticals
Calendar
12/02 - Q4 2025 Earnings Release
More about the company

Quotes

Date Price Change Volume
23/26/23 124.05 $ -0.28% 33,39,611
22/26/22 124.40 $ -0.54% 47,15,418
21/26/21 125.08 $ +1.49% 52,01,868
20/26/20 123.24 $ -1.13% 54,43,189
16/26/16 124.65 $ -0.50% 70,48,452

Delayed Quote Nyse, January 24, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
AAA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
124.05USD
Average target price
154.78USD
Spread / Average Target
+24.77%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ZTS Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition